Clal Biotechnology Industries Ltd. (CBI)

9 articles about Clal Biotechnology Industries Ltd. (CBI)

• 

  Neon Therapeutics to Launch IPO at $16 Per Share

  6/27/2018

  Cambridge, Massachusetts-based Neon Therapeutics is launching an initial public offering (IPO) of 6,250,000 shares of common stock at a price offering of $16 per share.

• Clal Biotech Appoints Julian Adams, Ph.D. As Chief Science Officer And President

  1/31/2017

• Clal Biotech Opts Out of Re-Acquiring Andromeda from Hyperion After Phase III Diabetes Drug Tanks

  10/7/2015

• Hyperion Therapeutics Enters Into Completion Of Phase III Clinical Trial, Option And Mutual Release Agreement With Clal Biotechnology Industries And Yeda Research and Development Company Ltd.

  2/17/2015

• Hyperion Therapeutics, Clal Biotechnology Industries Resolve Dispute Over $570 Million Biotech Problem

  10/7/2014

• Clal Biotechnology Industries Release: Andromeda Announces That Further Data Analyses Support Primary Endpoint in Andromeda Biotech's Phase III Clinical Study

  5/10/2012

• Teva Pharmaceutical Industries Limited, Clal Biotechnology Industries Raises Stake in Diabetes Treatment Developer, Andromeda; Teva and Clal to Invest $17.5 Million

  6/14/2010

• Yissum Ltd., Pontifax, and Clal Biotechnology Industries Invest $9 Million in Avraham Pharmaceuticals Ltd. to Pursue a Phase IIb Clinical Trial of Ladostigil, a Novel Drug for Treatment of Alzheimer's Disease

  4/14/2010

• Arte Ventures And Clal Biotechnology Industries Introduce A New Model For Biotech Investment Management

  3/26/2006